The Rare Cancer Network: Ongoing Studies and Future Strategy
Mahmut Özşahin(University of Lausanne), Robert C. Miller(Mayo Clinic), Xu Sun(Centre Hospitalier Universitaire de Besançon), Gamze Uğurluer(Acıbadem University), Banu Atalar(Istanbul University), Christopher L. Hallemeier(Mayo Clinic in Arizona), Juliette Thariat(Centre National de la Recherche Scientifique), Marco Krengli(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Yasmin Lassen–Ramshad(Aarhus University Hospital), Paul Van Houtte(Institut Jules Bordet), René-Olivier Mirimanoff(Clinique de La Source), Ryan K. Funk(Mayo Clinic in Arizona), Jessica Rooney(Mayo Clinic in Arizona), Kenneth Tou En Chang(KK Women's and Children's Hospital), Lan Jun Zhang(Sun Yat-sen University), Sunil Krishnan(Smith Family)
Cited by 8
Related Papers
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial
|The Lancet Oncology|2014|679
Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer
|Annals of Surgery|2019|445